BRUNETTI, LEONARDO
 Distribuzione geografica
Continente #
NA - Nord America 1.772
AS - Asia 1.284
EU - Europa 962
SA - Sud America 300
AF - Africa 65
OC - Oceania 3
Totale 4.386
Nazione #
US - Stati Uniti d'America 1.705
SG - Singapore 524
IT - Italia 267
BR - Brasile 250
CN - Cina 242
RU - Federazione Russa 161
HK - Hong Kong 152
DE - Germania 104
SE - Svezia 102
VN - Vietnam 98
FR - Francia 87
IN - India 78
GB - Regno Unito 69
AT - Austria 38
CA - Canada 34
FI - Finlandia 28
JP - Giappone 28
ID - Indonesia 27
BD - Bangladesh 21
PL - Polonia 21
AR - Argentina 19
TR - Turchia 18
TW - Taiwan 18
MX - Messico 16
ZA - Sudafrica 15
CI - Costa d'Avorio 14
NL - Olanda 14
BE - Belgio 12
IQ - Iraq 11
LT - Lituania 10
CO - Colombia 9
ES - Italia 9
MA - Marocco 9
AL - Albania 8
EC - Ecuador 8
KE - Kenya 8
KR - Corea 8
PH - Filippine 6
AE - Emirati Arabi Uniti 5
CL - Cile 5
MY - Malesia 5
UA - Ucraina 5
CH - Svizzera 4
CZ - Repubblica Ceca 4
EE - Estonia 4
EG - Egitto 4
OM - Oman 4
SA - Arabia Saudita 4
AU - Australia 3
AZ - Azerbaigian 3
BH - Bahrain 3
DK - Danimarca 3
IL - Israele 3
JM - Giamaica 3
LB - Libano 3
PA - Panama 3
PK - Pakistan 3
PY - Paraguay 3
UZ - Uzbekistan 3
VE - Venezuela 3
BY - Bielorussia 2
IE - Irlanda 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
MD - Moldavia 2
NG - Nigeria 2
NP - Nepal 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
ZW - Zimbabwe 2
AO - Angola 1
BB - Barbados 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CG - Congo 1
CR - Costa Rica 1
CV - Capo Verde 1
DM - Dominica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
GI - Gibilterra 1
GP - Guadalupe 1
GT - Guatemala 1
GY - Guiana 1
HN - Honduras 1
HR - Croazia 1
KH - Cambogia 1
KW - Kuwait 1
KZ - Kazakistan 1
LV - Lettonia 1
MR - Mauritania 1
NI - Nicaragua 1
NO - Norvegia 1
PE - Perù 1
PR - Porto Rico 1
Totale 4.380
Città #
Singapore 291
Ashburn 262
Chandler 174
San Jose 138
Hong Kong 136
Nyköping 96
Beijing 86
Fairfield 81
Dallas 55
Cambridge 51
Los Angeles 45
Council Bluffs 44
New York 41
Bari 40
Houston 40
Seattle 38
Ho Chi Minh City 34
Munich 34
Naples 34
Woodbridge 30
Lauterbourg 28
Wilmington 28
Jakarta 25
Helsinki 24
Tokyo 24
Hanoi 23
Frankfurt am Main 22
Moscow 22
Langenzersdorf 21
Lawrence 21
Santa Clara 21
Falkenstein 20
Fragagnano 20
North Bergen 20
Roxbury 19
São Paulo 19
London 17
Marseille 17
Rome 17
Inglewood 16
Chicago 15
Abidjan 14
Atlanta 14
Brooklyn 14
Warsaw 14
Milan 13
Ann Arbor 12
Denver 12
Montreal 12
Poplar 12
San Francisco 12
Brussels 11
Chennai 11
Johannesburg 11
Nuremberg 11
Boydton 9
Buffalo 9
Des Moines 9
Paris 9
Redondo Beach 9
Rio de Janeiro 9
Toronto 9
Kolkata 8
Orem 8
Düsseldorf 7
Guangzhou 7
Nairobi 7
Patna 7
Salt Lake City 7
Shanghai 7
Vienna 7
Amsterdam 6
Boston 6
Tirana 6
Wuxi 6
Baghdad 5
Bitonto 5
Brasília 5
Brindisi 5
Dong Ket 5
Draper 5
Elk Grove Village 5
Mexico City 5
Molfetta 5
New Delhi 5
Phoenix 5
Portsmouth 5
Shenzhen 5
Taichung 5
Taipei 5
Ankara 4
Belo Horizonte 4
Buenos Aires 4
Dhaka 4
Guarulhos 4
Haiphong 4
Lucca 4
Mumbai 4
Pune 4
Salerno 4
Totale 2.629
Nome #
DEVELOPMENT OF PHENOXYALKYLPIPERIDINES AS HIGH-AFFINITY SIGMA-1 (s1) RECEPTOR LIGANDS WITH POTENT ANTI-AMNESIC ACTIVITY 180
A Review of Recent Patents (2016-2019) on Plant Food Supplements with Potential Application in the Treatment of Neurodegenerative and Metabolic Disorders 164
Beyond the Canonical Endocannabinoid System. A Screening of PPAR Ligands as FAAH Inhibitors 157
Bone-seeking matrix metalloproteinase inhibitors for the treatment of skeletal malignancy 152
1,3,5-triazine derivatives as dual inhibitors of 5-HT6R/FAAH in search of new therapy for Alzheimer's disease 148
New Approaches to Cancer Therapy: Combining Fatty Acid Amide Hydrolase (FAAH) Inhibition with Peroxisome Proliferator-Activated Receptors (PPARs) Activation 144
Combining fatty acid amide hydrolase (FAAH) inhibition with peroxisome proliferator-activated receptor (PPAR) activation: a new potential multi-target therapeutic strategy for the treatment of Alzheimer’s disease 137
Derivatives of Tenuazonic Acid as Potential New Multi-Target Anti-Alzheimer’s Disease Agents 136
Deep Eutectic Solvents as Effective Reaction Media for the Synthesis of 2‐Hydroxyphenylbenzimidazole-based Scaffolds en Route to Donepezil‐Like Compounds 130
(2-Aminobenzothiazole)-Methyl-1,1-bisphosphonic acids: Targeting matrix metalloproteinase 13 inhibition to the bone 122
A New Series of Aryloxyacetic Acids Endowed with Multi-Target Activity towards Peroxisome Proliferator-Activated Receptors (PPARs), Fatty Acid Amide Hydrolase (FAAH), and Acetylcholinesterase (AChE) 119
Importance of Biometals as Targets in Medicinal Chemistry: An Overview about the Role of Zinc (II) Chelating Agents 118
A Chemoinformatics Search for Peroxisome Proliferator-Activated Receptors Ligands Revealed a New Pan-Agonist Able to Reduce Lipid Accumulation and Improve Insulin Sensitivity 118
A Chemical Modification of a Peroxisome Proliferator-Activated Receptor Pan Agonist Produced a Shift to a New Dual Alpha/Gamma Partial Agonist Endowed with Mitochondrial Pyruvate Carrier Inhibition and Antidiabetic Properties 117
Allosteric Modulators of Serotonin Receptors: A Medicinal Chemistry Survey 109
Development of N-(1-Adamantyl)benzamides as Novel Anti-Inflammatory Multitarget Agents Acting as Dual Modulators of the Cannabinoid CB2 Receptor and Fatty Acid Amide Hydrolase 109
Chiral pyrrolidines as multipotent agents in Alzheimer and neurodegenerative diseases 105
Natural Compounds for the Prevention and Treatment of Cardiovascular and Neurodegenerative Diseases 105
Development of novel phenoxyalkylpiperidines as high-affinity Sigma-1 (σ1) receptor ligands with potent anti-amnesic effect 102
A New Antidiabetic Agent Showing Short- and Long-Term Effects Due to Peroxisome Proliferator-Activated Receptor Alpha/Gamma Dual Agonism and Mitochondrial Pyruvate Carrier Inhibition 100
A NEW ANTIDIABETIC AGENT SHOWING PPARα/γ DUAL AGONISM AND MITOCHONDRIAL PYRUVATE CARRIER INHIBITION 98
FPR2 and brimstone: a novel approach for the treatment of neuroinflammation 95
Natural compounds as FAAH inhibitors: preliminary screening and potential developments 93
Can foods influence the onset and progress of neurodegenerative diseases? 93
Food Industry Byproducts as Starting Material for Innovative, Green Feed Formulation: A Sustainable Alternative for Poultry Feeding 90
Structure-based design of novel donepezil-like hybrids for a multi-target approach to the therapy of Alzheimer's disease 89
Novel Phenothiazine/Donepezil-Like Hybrids Endowed with Antioxidant Activity for a Multi-Target Approach to the Therapy of Alzheimer’s Disease 85
Identification of Natural Scaffolds as New Multi-Functional Agents for the Treatment of Alzheimer’s Disease 85
Rivastigmine structure-based hybrids as potential multi-target anti-Alzheimer’s drug candidates 84
Green Methods to Recover Bioactive Compounds from Food Industry Waste: A Sustainable Practice from the Perspective of the Circular Economy 82
IDENTIFICATION OF A NOVEL PPARRα/γ DUAL AGONIST SHOWING ANTIDIABETIC EFFECTS AND ABLE TO BIND TO CANONICAL AND ALLOSTERIC SITES OF ABLE TO BIND TO CANONICAL AND ALLOSTERIC SITES OF PPARγ 79
Novel small molecules for PPARs modulation and their potential use for treatment of metabolic disorders 76
Multi-Target Approach for the Design of New Compounds Potentially Useful for the Prevention and Treatment of Cardiovascular and/or Neurodegenerative Diseases 70
Multiple causes, multiple targets: FAAH as a centerpiece for therapy of multifactorial pathologies. 69
Discovery of a dual PPARα/γ partial agonist displaying antisteatotic and antidiabetic properties: in silico studies and X-ray structure determination 68
From classical MTDLs to a semi-synthetic innovative green approach: nature-inspired design as a new intriguing opportunity for new anti-Alzheimer’s drugs 67
Peroxisome Proliferator Activated Receptor (PPAR) agonists as Fatty Acid Amide Hydrolase (FAAH) inhibitors: screening and preliminary structure-activity relationships 64
New rivastigmine-like compounds for the potential treatment of Alzheimer’s disease: a multi-target approach 61
Rivastigmine-based hybrids: a multi-target approach to anti-Alzheimer’s drug design 53
Role of copper chelating agents: between old applications and new perspectives in neuroscience 52
Design, Synthesis, and Biological Evaluation of Novel Heteroaryl, Squaramide, and Indolcarboxamide Derivatives as Formyl Peptide Receptor 2 Agonists to Target Neuroinflammation 52
The pivotal role of pyrrolidine ring as multitarget scaffold in neurodegenerative diseases 50
New phenothiazine-donepezil like hybrids as potential Alzheimer’s disease multitarget drugs with antioxidant properties 47
Novel Rivastigmine Derivatives as Promising Multi-Target Compounds for Potential Treatment of Alzheimer’s Disease 44
Tackling neuroinflammation with H2S releasing FPR2 agonists 43
Rivastigmine-Benzimidazole Hybrids as Promising Multitarget Metal-Modulating Compounds for Potential Treatment of Neurodegenerative Diseases 39
A new potent and selective peroxisome proliferator-activated receptor alpha partial agonist displays anti-steatotic effects In vitro and behaves as a safe hypolipidemic and hypoglycemic agent in a diabetic mouse model 37
Multitarget 5-HT6R/FAAH/ChE ligands: the future of Alzheimer’s Disease treatment? 31
Novel rivastigmine structure-based hybrids for the potential treatment of Alzheimer’s disease 30
Novel Rivastigmine-Based Multitarget Hybrids For Potential Treatment of Alzheimer’s Disease: Cu(II) And Fe(III) Chelation Studies 29
The first-in-class 1,3,5-triazine-derived dual 5-HT6R/FAAH modulators in search for potential drug against neurodegenerative diseases with cognitive impairment 20
Hydrogen Sulfide (H2S)-Donating Formyl Peptide Receptor 2 (FPR2) Agonists: Design, Synthesis, and Biological Evaluation in Primary Mouse Microglia Culture 19
Beyond Radical Scavengers: Focus on NADPH Oxidases (NOX) Inhibitors as New Agents for Antioxidant Therapy in Alzheimer’s Disease 11
A Holistic Approach to Identifying a Positron Emission Tomography (PET) Tracer Candidate for In Vivo Imaging of Purinergic P2X7 Receptor in Neuroinflammation 4
Totale 4.581
Categoria #
all - tutte 18.361
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.361


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202170 0 0 0 0 0 0 0 0 0 45 12 13
2021/2022152 10 6 2 1 0 13 3 5 13 14 26 59
2022/2023418 33 61 36 33 32 52 7 57 68 9 19 11
2023/2024241 14 22 15 12 21 56 12 2 17 23 17 30
2024/20251.176 79 42 70 63 53 63 173 120 69 80 124 240
2025/20262.235 331 155 173 295 272 128 262 130 270 219 0 0
Totale 4.581